Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tagliabue, Elda"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
De Cecco, Loris, Berardi, Martina, Sommariva, Michele, Cataldo, Alessandra, Canevari, Silvana, Mezzanzanica, Delia, Iorio, Marilena V., Tagliabue, Elda, Balsari, Andrea
Publikováno v:
PLoS ONE; Mar2013, Vol. 8 Issue 3, p1-10, 10p
Autor:
Gabrielli, Federico, Salvi, Roberto, Garulli, Chiara, Kalogris, Cristina, Arima, Serena, Tardella, Luca, Monaci, Paolo, Pupa, Serenella M., Tagliabue, Elda, Montani, Maura, Quaglino, Elena, Stramucci, Lorenzo, Curcio, Claudia, Marchini, Cristina, Amici, Augusto
Publikováno v:
PLoS ONE; Mar2013, Vol. 8 Issue 3, p1-8, 8p
Autor:
Triulzi, Tiziana, Casalini, Patrizia, Sandri, Marco, Ratti, Manuela, Carcangiu, Maria L., Colombo, Mario P., Balsari, Andrea, Ménard, Sylvie, Orlandi, Rosaria, Tagliabue, Elda
Publikováno v:
PLoS ONE; Feb2013, Vol. 8 Issue 2, p1-10, 10p
Autor:
Tagliabue, Elda1, Agresti, Roberto1, Casalini, Patrizia1, Mariani, Luigi1, Carcangiu, Maria Luisa1, Balsari, Andrea2, Veronesi, Umberto3, Ménard, Sylvie1 sylvie.menard@istitutotumouri.mi.it
Publikováno v:
European Journal of Cancer. May2006, Vol. 42 Issue 8, p1057-1061. 5p.
Autor:
Michael F. Press, Dennis J. Slamon, Joan S. Brugge, Sara A. Hurvitz, Jason J. Zoeller, Judy Dering, Laura M. Selfors
Publikováno v:
PLoS ONE
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gen
Autor:
Viola Regondi, Stefania Arioli, Elda Tagliabue, Arianna Bonizzi, Francesca Bianchi, Beatrice Belmonte, Alessia Bertolotti, Claudio Tripodo, Andrea Balsari, Elena Fasano, Tiziana Triulzi, Loris De Cecco, Fabio Corsi, Martina Di Modica, Simone Guglielmetti, Giorgio Gargari, Laura Villani
Publikováno v:
Cancer research. 81(8)
Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclin
Autor:
Laura Botti, Maria Teresa Majorini, Claudio Tripodo, Alice Rigoni, Mario P. Colombo, Valeria Cancila, Claudia Chiodoni, Loris De Cecco, Daniele Lecis, Enrico Fontanella, Elena Jachetti, Matteo Dugo, Tiziana Triulzi, Elda Tagliabue
Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5961be16be787af28bb8b55bc9f2933
http://hdl.handle.net/10447/414607
http://hdl.handle.net/10447/414607
Autor:
Roberta Laranga, Lorena Landuzzi, Marianna L. Ianzano, Manuela Iezzi, Massimiliano Dall'Ora, Donatella Santini, Patrizia Nanni, Veronica Giusti, Enrico Di Oto, Mario Taffurelli, Giordano Nicoletti, Augusto Amici, Alessia Lamolinara, Serenella M. Pupa, Tania Balboni, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Pier Luigi Lollini, Elda Tagliabue, Carla De Giovanni
Publikováno v:
Oncotarget
// Arianna Palladini 1, * , Giordano Nicoletti 2, * , Alessia Lamolinara 3, * , Massimiliano Dall’Ora 1, * , Tania Balboni 1 , Marianna L. Ianzano 1 , Roberta Laranga 1 , Lorena Landuzzi 2 , Veronica Giusti 1 , Claudio Ceccarelli 1, 4 , Donatella S
Autor:
Maria Rosa Cappelletti, Elda Tagliabue, Loris De Cecco, Martina Di Modica, Tiziana Triulzi, Daniele Generali, Serena Di Cosimo, Biagio Paolini, Pier Luigi Lollini, Viola Regondi, Lucia Sfondrini
Publikováno v:
British Journal of Cancer
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of tr